{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:57:52Z","timestamp":1790816272963,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejca.2021.04.034","type":"journal-article","created":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T05:11:31Z","timestamp":1622956291000},"page":"165-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"special_numbering":"C","title":["Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-6537","authenticated-orcid":false,"given":"Michael","family":"Saerens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0137-447X","authenticated-orcid":false,"given":"Nele","family":"Brusselaers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Rottey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6795-7606","authenticated-orcid":false,"given":"Alexander","family":"Decruyenaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Creytens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5028-6305","authenticated-orcid":false,"given":"Lore","family":"Lapeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.04.034_bib1","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA - Canc J Clin"},{"key":"10.1016\/j.ejca.2021.04.034_bib2","series-title":"SEER cancer stat facts: bone and joint cancer","year":"2019"},{"key":"10.1016\/j.ejca.2021.04.034_bib3","series-title":"WHO classification of tumours of soft tissue and bone","year":"2020"},{"key":"10.1016\/j.ejca.2021.04.034_bib4","doi-asserted-by":"crossref","first-page":"iv268","DOI":"10.1093\/annonc\/mdy321","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(12)70346-7","article-title":"Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial","volume":"13","author":"Woll","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib6","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/archsurg.1983.01390080023007","article-title":"Metastatic patterns in soft-tissue sarcomas","volume":"118","author":"Vezeridis","year":"1983","journal-title":"Arch Surg-Chicago"},{"key":"10.1016\/j.ejca.2021.04.034_bib7","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3","article-title":"Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas \u2013 a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group","volume":"91","author":"Coindre","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.04.034_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","article-title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","volume":"388","author":"Tap","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.04.034_bib10","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2020.1707","article-title":"Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial","volume":"323","author":"Tap","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2021.04.034_bib11","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejca.2021.04.034_bib12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.ejca.2021.04.034_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Publ Health"},{"key":"10.1016\/j.ejca.2021.04.034_bib14","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","first-page":"143","article-title":"Choosing effect measures and computing estimates of effect","author":"Higgins","year":"2019"},{"key":"10.1016\/j.ejca.2021.04.034_bib15","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2021.04.034_bib16","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.ejca.2021.04.034_bib17","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1158\/1078-0432.CCR-16-2349","article-title":"Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: a phase Ib study of dasatinib plus ipilimumab","volume":"23","author":"D'Angelo","year":"2017","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.04.034_bib18","doi-asserted-by":"crossref","first-page":"11016","DOI":"10.1200\/JCO.2019.37.15_suppl.11016","article-title":"SAINT: results of a phase 1\/2 study of safety\/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma","volume":"37","author":"Gordon","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2020.01.028","article-title":"Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study","volume":"130","author":"Yang","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.04.034_bib20","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1001\/jamaoncol.2020.3689","article-title":"Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1\/2 nonrandomized clinical trial","volume":"6","author":"Pollack","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib21","article-title":"Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib\/II trial","volume":"8","author":"Martin-Broto","year":"2020","journal-title":"J Immunother Canc"},{"key":"10.1016\/j.ejca.2021.04.034_bib22","series-title":"ASCO 2020 virtual scientific programme: American society of clinical oncology","first-page":"186749","article-title":"A multicenter phase II study of nivolumab +\/\u2212 ipilimumab for patients with metastatic sarcoma (Alliance A091401): results of expansion cohorts","author":"Chen","year":"2020"},{"key":"10.1016\/j.ejca.2021.04.034_bib23","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D'Angelo","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib24","doi-asserted-by":"crossref","first-page":"11017","DOI":"10.1200\/JCO.2018.36.4_suppl.55","article-title":"A randomized phase 2 study of nivolumab monotherapy versus nivolumab combined with ipilimumab in patients with metastatic or unresectable gastrointestinal stromal tumor (GIST)","volume":"36","author":"Singh","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib25","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1002\/cncr.30738","article-title":"Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study","volume":"123","author":"Ben-Ami","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.04.034_bib26","doi-asserted-by":"crossref","unstructured":"Roland CL, Keung EZY, Lazar AJ, Torres KE, Wang WL, Guadagnolo A, et\u00a0al. Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). ASCO 2020 virtual scientific program: American society of clinical oncology. p. 11505.","DOI":"10.1200\/JCO.2020.38.15_suppl.11505"},{"key":"10.1016\/j.ejca.2021.04.034_bib27","doi-asserted-by":"crossref","unstructured":"Blay JY, Chevret S, Penel N, Bertucci F, Bompas E, saada-Bouzid E, et\u00a0al. High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: first results of the AcS\u00e9 Pembrolizumab study. In: Blay JY, editor. ESMO 2020 virtual congress.","DOI":"10.1016\/j.annonc.2020.08.1845"},{"key":"10.1016\/j.ejca.2021.04.034_bib28","doi-asserted-by":"crossref","first-page":"11015","DOI":"10.1200\/JCO.2019.37.15_suppl.11015","article-title":"Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated\/pleomorphic liposarcoma (LPS): final results of SARC028 expansion cohorts","volume":"37","author":"Burgess","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib29","series-title":"ESMO 2020 virtual congress","article-title":"PD1 blockade with pembrolizumab in classic and endemic Kaposi sarcoma: a multicenter phase II study","author":"Delyon","year":"2020"},{"key":"10.1016\/j.ejca.2021.04.034_bib30","doi-asserted-by":"crossref","first-page":"11010","DOI":"10.1200\/JCO.2019.37.15_suppl.11010","article-title":"Pilot study of NKTR214 and nivolumab in patients with sarcomas","volume":"37","author":"D'Angelo","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib31","doi-asserted-by":"crossref","first-page":"186779","DOI":"10.1200\/JCO.2020.38.15_suppl.11520","article-title":"SAINT: results of an expanded phase II study using safe amounts of ipilimumab (I), nivolumab (N), and trabectedin (T) as first-line treatment of advanced soft tissue sarcoma [NCT03138161]","volume":"38","author":"Gordon","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib32","article-title":"Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR TRIAL, NCCH1510): a multicenter, phase 2 clinical trial","author":"Kawai","year":"2020","journal-title":"CTOS"},{"key":"10.1016\/j.ejca.2021.04.034_bib33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jamaoncol.2019.6152","article-title":"Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene Laherparepvec in combination with pembrolizumab: a phase 2 clinical trial","volume":"6","author":"Kelly","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.11049","article-title":"A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma","volume":"37","author":"Kelly","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib35","series-title":"ASCO 2020 virtual scientific program: American society of clinical oncology","first-page":"186764","article-title":"A pilot study evaluating the safety, tolerability, and efficacy of doxorubicin and pembrolizumab in patients with metastatic or unresectable soft tissue sarcoma","author":"Livingston","year":"2020"},{"key":"10.1016\/j.ejca.2021.04.034_bib36","doi-asserted-by":"crossref","first-page":"168145","DOI":"10.1155\/2013\/168145","article-title":"A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma","volume":"2013","author":"Maki","year":"2013","journal-title":"Sarcoma"},{"key":"10.1016\/j.ejca.2021.04.034_bib37","doi-asserted-by":"crossref","unstructured":"Nathenson M, Choy E, Carr ND, Hibbard HD, Mazzola E, Catalano PJ, et\u00a0al. Phase II study of eribulin and pembrolizumab in patients (pts) with metastatic soft tissue sarcomas (STS): report of LMS cohort. ASCO 2020 virtual scientific program: American society of clinical oncology. p. 186758.","DOI":"10.1200\/JCO.2020.38.15_suppl.11559"},{"key":"10.1016\/j.ejca.2021.04.034_bib38","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1158\/1078-0432.CCR-20-2819","article-title":"Activity and safety of geptanolimab (GB226) for patients with unresectable, recurrent, or metastatic alveolar soft Part Sarcoma: a phase II, single-arm study","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.04.034_bib39","doi-asserted-by":"crossref","unstructured":"Somaiah N, Conley AP, Lin HY, Amini B, Sabir SH, Araujo DM, et\u00a0al. A phase II multi-arm study of durvalumab and tremelimumab for advanced metastatic sarcomas. ASCO 2020 virtual scientific symposium. p. 11509.","DOI":"10.1200\/JCO.2020.38.15_suppl.11509"},{"key":"10.1016\/j.ejca.2021.04.034_bib40","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","article-title":"Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas a phase 2 clinical trial","volume":"4","author":"Toulmonde","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib42","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib43","series-title":"ASCO 2020 virtual scientific program: American society of clinical oncology","first-page":"11518","article-title":"A phase II single-arm study of nivolumab and ipilimumab (Nivo\/Ipi) in previously treated classical Kaposi sarcoma (CKS)","author":"Zer","year":"2020"},{"key":"10.1016\/j.ejca.2021.04.034_bib44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejca.2014.11.008","article-title":"Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis","volume":"51","author":"Taieb","year":"2015","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.04.034_bib45","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1002\/cncr.27624","article-title":"Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy","volume":"118","author":"Stacchiotti","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.04.034_bib46","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.clon.2017.04.002","article-title":"Role of imaging in response assessment and individualised treatment for sarcomas","volume":"29","author":"Choi","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib47","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.04.034_bib48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejca.2018.10.024","article-title":"Activity of axitinib in progressive advanced solitary fibrous tumour: results from an exploratory, investigator-driven phase 2 clinical study","volume":"106","author":"Stacchiotti","year":"2019","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.04.034_bib49","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/bjc.2012.328","article-title":"Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study","volume":"107","author":"Sleijfer","year":"2012","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2021.04.034_bib50","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40265-020-01327-7","article-title":"Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma","volume":"80","author":"Hirsch","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejca.2021.04.034_bib51","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib52","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.04.034_bib53","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.04.034_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.577766","article-title":"Sunitinib exerts in\u00a0vitro immunomodulatory activity on sarcomas via dendritic cells and synergizes with PD-1 blockade","volume":"12","author":"Ocadlikova","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2021.04.034_bib55","article-title":"Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial","volume":"4","author":"D'Angelo","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib56","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib57","series-title":"CTOS 2020 abstract 3464044. Virtual symposium","article-title":"Efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: results from a retrospective world-wide registry","author":"Hindi","year":"2020"},{"key":"10.1016\/j.ejca.2021.04.034_bib58","series-title":"Genetic immunosignatures associate with progression-free survival in advanced soft tissue sarcoma patients treated on a Phase 2 trial of the VEGF receptor inhibitor axitinib plus pembrolizumab","author":"Wilky","year":"2018"},{"key":"10.1016\/j.ejca.2021.04.034_bib59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.ejca.2021.04.034_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib61","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1002\/cncr.30726","article-title":"T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas","volume":"123","author":"Pollack","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.04.034_bib62","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.11008","article-title":"Integrative assessment of expression and prognostic value of PDL1, IDO, and kynurenine in 371 primary soft tissue sarcomas with genomic complexity","volume":"34","author":"Toulmonde","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.04.034_bib63","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.humpath.2014.11.001","article-title":"Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment","volume":"46","author":"D'Angelo","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ejca.2021.04.034_bib64","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12967-018-1658-5","article-title":"Status of programmed death-ligand 1 expression in sarcomas","volume":"16","author":"Park","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2021.04.034_bib65","doi-asserted-by":"crossref","first-page":"1792036","DOI":"10.1080\/2162402X.2020.1792036","article-title":"Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma","volume":"9","author":"Dufresne","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejca.2021.04.034_bib66","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"10.1016\/j.ejca.2021.04.034_bib67","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921002872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:32:33Z","timestamp":1760733153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921002872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":67,"alternative-id":["S0959804921002872"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.034","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.04.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}